B-cell Non-Hodgkin’s Lymphoma Incident Cases Grow to 111,366 by 2023

Date: 14-May-2014

RnR Market Research

Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. This epidemiological analysis focuses specifically on four subtypes of B-cell NHL: follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma.

This report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NHL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma segmented by age (30 to ≥85 years) and sex. For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 6MM.

Epidemiologists forecast an increase in the incident cases of B-cell NHL in the 6MM, from 89,455 incident cases in 2013 to 111,366 incident cases in 2023, with an annual growth rate (AGR) of 2.45%. Throughout the forecast period, the US will have the highest number of incident cases of B-cell NHL, as well as 36% growth during the forecast period, ending with 56,033 incident cases in 2023. Additionally, each of the 6MM will see an increase in incident cases over the 10-year forecast period.